ClinicalTrials.gg
CompletedNCT02489227PsOsimUpdated Apr 8, 2020Results posted

Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis

A Phase 3 interventional study of CHS-1420 and Adalimumab in Plaque Psoriasis, sponsored by Coherus Biosciences, Inc.. Completed at 99 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-08.

Sponsored by Coherus Biosciences, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
545
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Enrollment
81st of 673
545 · median 77
Started
2015
with 43 others
Phase 3
188 of 764
6 open now
Registered
362nd of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 81st largest by enrollment of the 673 interventional ones that give a count, is one of 44 that started in 2015, is one of 188 in phase 3, and was the 362nd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

This is a 3-period study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis.

Read the detailed description

This is a 55-week, randomized, double-blind, active-control, parallel group, multicenter, global study in subjects with active, moderate to severe, chronic PsO.

The study will consist of 24 weeks of administration of blinded study drug, divided into Treatment Period 1 and Treatment Period 2, then 23 weeks of administration of open-label CHS-1420 and a Follow-up visit 8 weeks after the last dose. Subjects who meet inclusion/exclusion criteria will be stratified by body mass index (BMI), and age and randomized 1:1 to receive CHS-1420 or Humira in Treatment Period 1. Subjects assigned to CHS-1420 will continue to receive CHS-1420 in Period 2. Subjects assigned to Humira in Period 1 will be randomly assigned (1:1) to either continue with Humira in Treatment Period 2 or to switch to CHS-1420 in Treatment Period 2. All subjects will receive open label CHS-1420 in Treatment Period 3.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • PsO
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adults
  • PsO diagnosis for 6 months
  • Active disease: PASI greater than or equal to 12, Physician's Static Global Assessment (PSGA) score greater than or equal to 3 (based on a scale of 0-5),
  • Body Surface Area (BSA) involved with PsO greater than or equal to 10%

Exclusion criteria

Exclusion Criteria:

  • Forms of psoriasis other than PsO
  • Drug induced psoriasis
  • Positive QuantiFERON-tuberculosis (TB) Gold Test
  • Presence of significant comorbid conditions
  • Chemistry and hematology values outside protocol specified range
  • Major systemic infections
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
545 participants (actual)

Study arms

  • Active comparator
    Humira (adalimumab)

    Adalimumab (Humira) 40mg 2 doses at week 0/Day 0, then 1 dose every 2 weeks starting at Week 1 until Week 15. At Week 16 subjects initially randomized to adalimumab will be assigned (1:1) to CHS-1420 or continue adalimumab treatment, 1 dose every 2 weeks for weeks 17-23. The assignments for treatment sequences (Treatment Period 1 and Treatment Period 2) were made randomly at the beginning of Treatment Period 1. At week 24 subjects will switch to CHS-1420 open label until study end.

    Drug: CHS-1420 · Drug: Adalimumab

  • Experimental
    CHS-1420

    CHS-1420 40mg 2 doses at Week 0/Day 0 then 1 dose every 2 weeks starting at Week 1 for 23 weeks. At Week 24 subjects will continue on to CHS-1420 open label until study end.

    Drug: CHS-1420

Interventions

06

What researchers measure

Primary outcomes

  1. Difference Between the Percentage of Subjects in Each Treatment Group Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI-75) at Week 12

    The efficacy success criterion was the equivalence between CHS-1420 and Humira at Week 12. Equivalence was based upon 2-sided 95% confidence interval (CI) for the difference between the proportions of subjects in the CHS-1420 and Humira groups achieving PASI-75 at Week 12. If the 95% CI lay entirely within the interval (-15%, 15%), equivalence was established.

    Time frame: 12 weeks

07

Results

Posted Oct 18, 2019

Participant flow

Participant flow — Overall Study
MilestoneCHS-1420Humira (Adalimumab) Reassigned to CHS-1420Humira (Adalimumab)
Started274135136
Completed220101117
Not completed543419

Outcome measures

PrimaryDifference Between the Percentage of Subjects in Each Treatment Group Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI-75) at Week 12

The efficacy success criterion was the equivalence between CHS-1420 and Humira at Week 12. Equivalence was based upon 2-sided 95% confidence interval (CI) for the difference between the proportions of subjects in the CHS-1420 and Humira groups achieving PASI-75 at Week 12. If the 95% CI lay entirely within the interval (-15%, 15%), equivalence was established.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Difference Between the Percentage of Subjects in Each Treatment Group Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI-75) at Week 12
ParticipantsHumira (Adalimumab)CHS-1420
Difference Between the Percentage of Subjects in Each Treatment Group Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI-75) at Week 12203211

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Period 1: CHS-14200/274 (0%)4/274 (1.5%)41/274 (15%)
Treatment Period 1: Humira (Adalimumab)0/271 (0%)6/271 (2.2%)38/271 (14%)
Treatment Period 2: CHS-1420/CHS-14200/255 (0%)4/255 (1.6%)0/255 (0%)
Treatment Period 2: Humira/CHS-14200/126 (0%)3/126 (2.4%)0/126 (0%)
Teatment Period 2: Humira/Humira0/130 (0%)1/130 (0.8%)0/130 (0%)
Treatment Period 3: Open Label CHS-1420 Extension1/474 (0.2%)4/474 (0.8%)0/474 (0%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventTreatment Period 1: CHS-1420Treatment Period 1: Humira (Adalimumab)Treatment Period 2: CHS-1420/CHS-1420Treatment Period 2: Humira/CHS-1420Teatment Period 2: Humira/HumiraTreatment Period 3: Open Label CHS-1420 Extension
Anal fistulaGastrointestinal disorders0/2740/2710/2551/1260/1300/474
BronchitisInfections and infestations0/2740/2710/2551/1260/1300/474
Lobar pneumoniaInfections and infestations0/2740/2710/2551/1260/1300/474
Calculus uretericRenal and urinary disorders0/2740/2710/2551/1260/1300/474
TuberculosisInfections and infestations0/2740/2710/2550/1261/1300/474
GastritisGastrointestinal disorders0/2740/2711/2550/1260/1300/474
Inguinal HerniaGastrointestinal disorders0/2740/2711/2550/1260/1300/474
Limb injuryInjury, poisoning and procedural complications0/2740/2711/2550/1260/1300/474
ObesityMetabolism and nutrition disorders0/2740/2711/2550/1260/1300/474
DiarrheaGastrointestinal disorders0/2741/2710/2550/1260/1300/474
Most frequent other events
Most frequent other events
EventTreatment Period 1: CHS-1420Treatment Period 1: Humira (Adalimumab)Treatment Period 2: CHS-1420/CHS-1420Treatment Period 2: Humira/CHS-1420Teatment Period 2: Humira/HumiraTreatment Period 3: Open Label CHS-1420 Extension
NasopharyngitisInfections and infestations24/27424/2710/2550/1260/1300/474
Upper respiratory tract infectionInfections and infestations17/27414/2710/2550/1260/1300/474

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CHS-1420Humira (Adalimumab) Reassigned to CHS-1420Humira (Adalimumab)Total
<=18 years0000
Between 18 and 65 years256124127507
>=65 years1811938
Sex: Female, Male
Sex: Female, Male(Participants)CHS-1420Humira (Adalimumab) Reassigned to CHS-1420Humira (Adalimumab)Total
Female823138151
Male19210498394
08

Study locations

99 sites
  • Sadra Sasha Jazayeri, MD
    Phoenix, Arizona 85032, United States
  • Encino Research Center
    Encino, California 91436, United States
  • Center for Dermatology and Laser Surgery
    Sacramento, California 95819, United States
  • Kenneth M Stein, MD
    Santa Rosa, California 95405, United States
  • HealthCare Partners Medical Group Clinical Research Center
    Torrance, California 90503, United States
  • Horizons Clinical Research Center, LLC.
    Denver, Colorado 80220, United States
  • New England Research Associates LLC
    Trumbull, Connecticut 06611, United States
  • Francisco A Kerdel, MD
    Coral Gables, Florida 33134, United States
  • Linda Tripodis Murray, DO
    Pinellas Park, Florida 33781, United States
  • ACRC-Dermatology
    West Palm Beach, Florida 33406, United States
  • Mark A Knautz, MD
    Marietta, Georgia 30060, United States
  • The Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • Grekin Skin Institute
    Warren, Michigan 48088, United States
  • Jack C Scott, MD
    Edina, Minnesota 55435, United States
  • Central Dermatology
    Saint Louis, Missouri 63117, United States
  • Craig L Leonardi, MD
    Saint Louis, Missouri 63117, United States
  • PMG Research of Raleigh, LLC
    Cary, North Carolina 27518, United States
  • Box Arthritis & Rheumetology of the Carolinas
    Charlotte, North Carolina 28210, United States
  • Michael Joseph Noss, MD
    Cincinnati, Ohio 45249, United States
  • Central Sooner Research
    Norman, Oklahoma 73031, United States
  • Health Research of Oklahoma
    Oklahoma City, Oklahoma 73103, United States
  • Dermatology and Skin Surgery Center, PC
    Exton, Pennsylvania 19341, United States
  • James Henry Kopp, MD
    Anderson, South Carolina 29621, United States
  • PMG Research of Bristol, LLC
    Bristol, Tennessee 37620, United States
  • Arlington Research Center, Inc.
    Arlington, Texas 76011, United States
  • Center for Clinical Studies TMC/ Museum District Office
    Houston, Texas 77004, United States
  • Center for Clinical Studies
    Houston, Texas 77065, United States
  • Center for Clinical Studies
    Webster, Texas 77598, United States
  • Center for Dermatology and Venerology Diseases, EOOD, Sofia City
    Sofia, 1415, Bulgaria
  • Kingsway Clinical Research
    Etobicoke, Ontario M8X 1Y9, Canada
  • Dermatology Center
    London, Ontario N5X 2P1, Canada
  • Lynderm Research Inc.
    Markham, Ontario L3P 1X2, Canada
  • North Bay Dermatology Centre
    North Bay, Ontario P1B 3Z7, Canada
  • Research by ICLS
    Oakville, Ontario L6J 7W5, Canada
  • Skin Centre for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • The Centre for Dermatology
    Richmond Hill, Ontario L4B 1A5, Canada
  • Research Toronto
    Toronto, Ontario M4W 2N2, Canada
  • Research Toronto
    Toronto, Ontario M5S 3B4, Canada
  • Probity Medical Research, Inc.
    Waterloo, Ontario N2J 1C4, Canada
  • Windsor Clinical Research
    Windsor, Ontario N8W 5L7, Canada
  • Clinica Dermacross SA
    Santiago, 7640881, Chile
  • Centro Intrnacional de Estudios Clinicos- CIEC
    Santiago, 8420383, Chile
  • Antonio Guglielmetti, MD
    Viña Del Mar, 2520000, Chile
  • Naftalan, Special Hospital for Medical Rehabilitation
    Ivanić-Grad, 10310, Croatia
  • Clinical Hospital Centre "Osijek"
    Osijek, 31000, Croatia
  • Tartu University Hospital, Dermatology Clinic
    Raja, Tartu 50417, Estonia
  • Innomedica OÜ
    Tallinn, 10117, Estonia
  • North Estonian Medical Centre Foundation Skin and Sexual Diseases Center
    Tallinn, 13419, Estonia
  • Aleksandre Aladshvili Clinic LLC
    Tbilisi, 0102, Georgia
  • Tbilisi State Medical University Alexandre Aladashvili University Clinic
    Tbilisi, 0144, Georgia
  • Scientific/Research National Center of Dermatology and Venereology
    Tbilisi, 0159, Georgia
  • Health Institute LLC
    Tbilisi, 0160, Georgia
  • Medical Center Clto Ltd
    Tbilisi, 0179, Georgia
  • Department of Dermatology- Ha'Emek Medical Center
    Afula, 1834111, Israel
  • Meir Medical Center Dermatologic Clinic
    Kfar Saba, 4428164, Israel
  • Rabin Medical Center Department of Dermatology
    Petah tikva, 49100, Israel
  • Department of Dermatology Phototherapy and Day Care Center
    Ramat Gan, 52621, Israel
  • Department of Clinical and Molecular Sciences Dermatologic Clinic
    Ancona, Italy
  • Department of Internal Medicine and Medical Specialties Unit of Dermatology
    Reggio Emilia, Italy
  • Istituto di Clinica Dermosifilopatica Univeristà Cattolica del S.Cuore
    Rome, Italy
  • Janis Kisis, MD
    Jurmala, LV-2008, Latvia
  • Riga 1st Hospital Skin and Sexually Transmitted Diseases Clinical Centre
    Riga, LV-1001, Latvia
  • Kristine Berzina, MD, PhD
    Riga, LV-1046, Latvia
  • PMSI Institute of Cardiology
    Chisinau, MD2025, Moldova, Republic of
  • Zdrowie Osteo-Medic s.c.
    Białystok, 15-351, Poland
  • ClinicMed Badurski i wspólnicy Spółka Jawna
    Białystok, 15-879, Poland
  • Centrum Badań Kliniccznych
    Gdańsk, 80-456, Poland
  • Grażyna Pulka Specjalistyczny Ośrodek, "ALL-MED"
    Krakow, 31-023, Poland
  • CenterMed Kraków Śp. z o. o.
    Kraków, 31-530, Poland
  • Synexus Polska Sp. z o. o. Oddzial w Poznaniu
    Poznań, 60-702, Poland
  • Niepubliczny Zaklad Opieki Zdrowtnej "NASZ LEKARZ"
    Toruń, 87-100, Poland
  • Synexus Polska Śp. z o.o.
    Warsaw, 01-192, Poland
  • Wojewodzki Szpital Specjalistyczny we Wrocławiu, Oddział Dermatologiczny
    Wrocław, 51-124, Poland
  • Altay State Medical University
    Barnaul, 651045, Russian Federation
  • Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology of the Public Health Department of Moscow
    Moscow, 109044, Russian Federation
  • Moscow State University and Dentistry named after Evdokimov
    Moscow, 121614, Russian Federation
  • Imc "Sogaz"
    Saint Petersburg, 191186, Russian Federation
  • Olga Mikerina, MD
    Saint Petersburg, 195257, Russian Federation
  • Alliance Biomedical Group
    Saint Petersburg, 94356, Russian Federation
  • Clinic of Skin and Venereal Diseases of the Saratov State Medical University
    Saratov, 410028, Russian Federation
  • DOST - Dermatovenerologicke oddelenie sanatorneho typu
    Svidník, 089 01, Slovakia
  • Panorama Medical Centre, Room 136
    Panorama, Cape Town 7500, South Africa
  • Medicross Pretoria West 1st Floor
    Pretoria West, Pretoria 0183, South Africa
  • Zubar Fazal Ahmed Vawda. MD
    Durban, 4091, South Africa
  • The Park, Room 201, 2nd Floor
    Pinelands, 7405, South Africa
  • Synopsis Research cc
    Rondebosch, 7700, South Africa
  • Synexus Heiderberg Clinical Research Centre
    Somerset West, 7130, South Africa
  • Clinical Projects Research SA (PTY) Ltd.
    Worcester, 6850, South Africa
  • Medical Center Private Enterprise "Dzerkalo"
    Dnipropetrovs'k, 49044, Ukraine
  • Ivano-Frankivsk National Medical Univeristy, Dept. of Dermatology and Venereology based on Ivano-Frankivsk Regional Clinical Dermatology and Venereology Dispensary
    Ivano-Frankivs'k, 76018, Ukraine
  • Municipal Healthcare Institution "Kharkiv City Dermatovenereological Dispensary #2
    Kharkiv, 61038, Ukraine
  • Khmel'nytskyy Regional Dermatovenereological Dispensary
    Khmel'nyts'kyy, 29009, Ukraine
  • National Medical University named after O.O.Bohomolets, Dept. of Dermatology and Venereology based on Oleksandrivska Clinical Hospital of Kyiv City, Dept. of Dermatology
    Kyiv, 01601, Ukraine
  • National Medical University named after Danyla Galytskoho, Dept. of Family Medicine and Dermatology, Venereology based on Dept. of Dermatovenereology of the clinical Hospital of Ukrainian State Border Guard Services
    Lviv, 79014, Ukraine
  • Odesa National Medical University, Department of Dermatic and Venereologic Diseases based on Odesa Regional Dermatovenereological Dispensary
    Odesa, 65006, Ukraine
  • Municipal Institution "Rivne Regional Dermatology and Venereology Dispensary" of Rivne Regional Council
    Rivne, 33028, Ukraine
  • Municipal Institution of Ternopil Regional Council Ternopil Regional Clinical Dermatovenereological Dispensary
    Ternopil', 46006, Ukraine
  • Diagnostic and Treatment Dermatology and Gynecology Center
    Uzhhorod, 88000, Ukraine
  • Municipal Institution "Zaporizhzhya Regional Dermatology and Venereology Clinical Dispensary" of Zaporizhzhya Regional Council
    Zaporizhzhya, 69063, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2015, a primary completion of May 2016 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2019, 3 years 5 months after primary completion. A results delay was requested in May 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2015
First posted
Jul 2, 2015
Start
Aug 2015
Primary completionActual
May 6, 2016
CompletionActual
Mar 2017
Results delay requested
May 31, 2017
Results first posted
Oct 18, 2019
Last update
Apr 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02489227
Lead sponsor
Coherus Biosciences, Inc.
Responsible party
Sponsor
First posted
Jul 2, 2015
Start date
Aug 2015
Primary completion
May 6, 2016
Completion
Mar 2017
Results posted
Oct 18, 2019
Last update
Apr 8, 2020

Study contacts

Barbara P Finck, M.D.
study director · Coherus Biosciences, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion